PTK2 and carcinoma: Notably while, in vivo, the FAK inhibitor likely affects other stromal cells and modulates their behavior (e.g., reducing ECM production by myofibroblasts), our in vitro system allows us to test the effect of the inhibitor specifically on primary carcinoma cells.